Specialty medical injectable drug program updates: Viltespo™

Specialty medical injectable drug requirements have recently changed. Please review the following table to learn more.

Drug Name UnitedHealthcare Commercial Treatment Uses
Viltepso™ X For the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 53 skipping therapy.

For more information, download the UnitedHealthcare Commercial Plan Review at Launch Medication List.


Note: Certain specialty medical injectable drug programs and updates will not be implemented for providers practicing in Rhode Island, with respect to certain commercial members, until reviewed and approved by the Rhode Island Office of Health Insurance Commissioner (OHIC). We encourage providers practicing in Rhode Island to call in to confirm if prior authorization is required. This exception does not apply to Medicaid and Medicare.